Wanbangde Pharmaceutical Holding Group Co., Ltd. / Fundamentals
Income statement
- Net revenue
€151.00M - Cost of goods sold
€90.20M - Gross profit
€60.80M - SG&A expenses
€28.78M - R&D expenses
€7.56M - EBITDA
€10.33M - D&A
€0.00 - EBIT
€5.55M - Interest expenses
€2.13M - EBT
€5.45M - Tax expenses
€2.59M - Net income
€3.71M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€9.46M - Changes in working capital
€0.00 - Operating cash flow
€10.41M - Capex
€26.35M - Other investing cash flow
€19.51M - Net investing cash flow
-€19.35M - Total cash dividends paid
-€10.59M - Issuance of common stock
€0.00 - Debt repayment
€474.85K - Other financing cash flow
€29.19M - Net financing cash flow
€19.08M - Foreign exchange effects
-€14.08K - Net change in cash
€5.43M - Cash at end of period
€21.54M - Free cash flow
€36.76M
Balance sheet
- Cash and cash equivalents
€23.26M - Cash and short-term investments
€23.26M - Total receivables
€110.82M - Inventory
€27.11M - Other current assets
€48.67M - Total current assets
€209.85M - Property, plant & equipment
€182.77M - Goodwill
€15.14M - Intangible assets
€60.83M - Long-term investments
€0.00 - Other non-current assets
€41.33M - Total non-current assets
€317.01M - Total assets
€526.86M - Accounts payable
€28.73M - Short-term debt
€83.63M - Other current liabilities
€16.31M - Total current liabilities
€132.36M - Long-term debt
€19.82M - Deferred tax liabilities
€5.34M - Other non-current liabilities
€28.66M - Total non-current liabilities
€64.49M - Total liabilities
€196.85M - Common stock
€72.78M - Retained earnings
€198.63M - Other equity
€0.00 - Total equity
€330.01M - Total liabilities and shareholders' equity
€526.86M
Company information
- Market capitalization
€483.64M - Employees
1.6K - Enterprise Value
€5.49B
Company ratios
- Gross margin
-
40.3% Better than peer group: 34.2% - EBITDA margin
-
6.8% Worse than peer group: 17.6% - EBIT margin
-
3.7% Worse than peer group: 9.4% - EBT margin
-
3.6% Worse than peer group: 10.3% - Net margin
-
2.5% Worse than peer group: 9.0% - ROE
-
1.1% Much worse than peer group: 33.1% - ROA
-
0.7% Even with peer group: 3.1% - Asset turnover
-
28.7% Much worse than peer group: 55.4% - FCF margin
-
-10.6% Even with peer group: -14.7% - FCF yield
-3.3% - Efficiency ratio
93.2% - Net sales per employee
-
€94.08K - Net income per employee
-
€2.31K